Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive KarXT for Mania in Bipolar-I Disorder
NCT07140913Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of xanomeline + trospium chloride in bipolar I disorder, sponsored by Bristol Myers Squibb. Started Oct 2025; status: recruiting.
02
Drugs
xanomeline + trospium chloride
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT07140913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140913.